

Ho Tsoi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8156793/publications.pdf>

Version: 2024-02-01

9
papers

120
citations

1478505

6
h-index

1474206

9
g-index

9
all docs

9
docs citations

9
times ranked

81
citing authors

#	ARTICLE	IF	CITATIONS
1	Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer. <i>Life</i> , 2022, 12, 93.	2.4	4
2	Androgen Receptor as an Emerging Feasible Biomarker for Breast Cancer. <i>Biomolecules</i> , 2022, 12, 72.	4.0	18
3	Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast Cancer. <i>Cancers</i> , 2022, 14, 1251.	3.7	11
4	Targeting the IL-6/STAT3 Signalling Cascade to Reverse Tamoxifen Resistance in Estrogen Receptor Positive Breast Cancer. <i>Cancers</i> , 2021, 13, 1511.	3.7	22
5	KPNA1 regulates nuclear import of NCOR2 splice variant BQ323636.1 to confer tamoxifen resistance in breast cancer. <i>Clinical and Translational Medicine</i> , 2021, 11, e554.	4.0	10
6	Repurposing hyperpolarization-activated cyclic nucleotide-gated channels as a novel therapy for breast cancer. <i>Clinical and Translational Medicine</i> , 2021, 11, e578.	4.0	7
7	A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2. <i>Cancers</i> , 2020, 12, 533.	3.7	7
8	Phosphorylation independent eIF4E translational reprogramming of selective mRNAs determines tamoxifen resistance in breast cancer. <i>Oncogene</i> , 2020, 39, 3206-3217.	5.9	18
9	BQ323636.1, a Novel Splice Variant to NCOR2, as a Predictor for Tamoxifen-Resistant Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3681-3691.	7.0	23